---
keywords:
  - Neuro-oncology
  - Foundation Model
  - Distributionally Robust Optimization
  - Self-supervised Learning
  - Molecular Marker Prediction
category: cs.CV
publish_date: 2025-09-22
arxiv_id: 2509.15416
---

<!-- KEYWORD_LINKING_METADATA:
{
  "processed_timestamp": "2025-09-23T11:57:30.429106",
  "vocabulary_version": "1.0",
  "selected_keywords": [
    "Neuro-oncology",
    "Foundation Model",
    "Distributionally Robust Optimization",
    "Self-supervised Learning",
    "Molecular Marker Prediction"
  ],
  "rejected_keywords": [],
  "similarity_scores": {
    "Neuro-oncology": 0.72,
    "Foundation Model": 0.7,
    "Distributionally Robust Optimization": 0.75,
    "Self-supervised Learning": 0.78,
    "Molecular Marker Prediction": 0.73
  },
  "extraction_method": "AI_prompt_based",
  "budget_applied": true,
  "candidates_json": {
    "candidates": [
      {
        "surface": "Neuro-oncology",
        "canonical": "Neuro-oncology",
        "aliases": [
          "Neuro Oncology",
          "NeuroOncology"
        ],
        "category": "unique_technical",
        "rationale": "This is a specialized field that connects to research in both neurology and oncology, providing a specific context for the study.",
        "novelty_score": 0.75,
        "connectivity_score": 0.65,
        "specificity_score": 0.85,
        "link_intent_score": 0.72
      },
      {
        "surface": "Foundation Model",
        "canonical": "Foundation Model",
        "aliases": [
          "FM"
        ],
        "category": "broad_technical",
        "rationale": "Foundation models are a fundamental concept in AI, linking various machine learning approaches.",
        "novelty_score": 0.55,
        "connectivity_score": 0.78,
        "specificity_score": 0.6,
        "link_intent_score": 0.7
      },
      {
        "surface": "Distributionally Robust Optimization",
        "canonical": "Distributionally Robust Optimization",
        "aliases": [
          "DRO"
        ],
        "category": "specific_connectable",
        "rationale": "DRO is a specific technique that enhances model robustness, crucial for cross-institutional generalization.",
        "novelty_score": 0.68,
        "connectivity_score": 0.72,
        "specificity_score": 0.8,
        "link_intent_score": 0.75
      },
      {
        "surface": "Self-supervised Learning",
        "canonical": "Self-supervised Learning",
        "aliases": [
          "SSL"
        ],
        "category": "specific_connectable",
        "rationale": "This is a key approach in training models without labeled data, relevant for the paper's methodology.",
        "novelty_score": 0.5,
        "connectivity_score": 0.85,
        "specificity_score": 0.7,
        "link_intent_score": 0.78
      },
      {
        "surface": "Molecular Marker Prediction",
        "canonical": "Molecular Marker Prediction",
        "aliases": [
          "Marker Prediction"
        ],
        "category": "unique_technical",
        "rationale": "Predicting molecular markers is a unique task in this study, linking to precision medicine.",
        "novelty_score": 0.7,
        "connectivity_score": 0.6,
        "specificity_score": 0.82,
        "link_intent_score": 0.73
      }
    ],
    "ban_list_suggestions": [
      "method",
      "performance",
      "experiment"
    ]
  },
  "decisions": [
    {
      "candidate_surface": "Neuro-oncology",
      "resolved_canonical": "Neuro-oncology",
      "decision": "linked",
      "scores": {
        "novelty": 0.75,
        "connectivity": 0.65,
        "specificity": 0.85,
        "link_intent": 0.72
      }
    },
    {
      "candidate_surface": "Foundation Model",
      "resolved_canonical": "Foundation Model",
      "decision": "linked",
      "scores": {
        "novelty": 0.55,
        "connectivity": 0.78,
        "specificity": 0.6,
        "link_intent": 0.7
      }
    },
    {
      "candidate_surface": "Distributionally Robust Optimization",
      "resolved_canonical": "Distributionally Robust Optimization",
      "decision": "linked",
      "scores": {
        "novelty": 0.68,
        "connectivity": 0.72,
        "specificity": 0.8,
        "link_intent": 0.75
      }
    },
    {
      "candidate_surface": "Self-supervised Learning",
      "resolved_canonical": "Self-supervised Learning",
      "decision": "linked",
      "scores": {
        "novelty": 0.5,
        "connectivity": 0.85,
        "specificity": 0.7,
        "link_intent": 0.78
      }
    },
    {
      "candidate_surface": "Molecular Marker Prediction",
      "resolved_canonical": "Molecular Marker Prediction",
      "decision": "linked",
      "scores": {
        "novelty": 0.7,
        "connectivity": 0.6,
        "specificity": 0.82,
        "link_intent": 0.73
      }
    }
  ]
}
-->

# NeuroRAD-FM: A Foundation Model for Neuro-Oncology with Distributionally Robust Training

**Korean Title:** ì‹ ê²½ë°©ì‚¬ì„ í•™-FM: ë¶„í¬ì ìœ¼ë¡œ ê²¬ê³ í•œ í›ˆë ¨ì„ í†µí•œ ì‹ ê²½ì¢…ì–‘í•™ì˜ ê¸°ì´ˆ ëª¨ë¸

## ğŸ“‹ ë©”íƒ€ë°ì´í„°

**Links**: [[daily_digest_20250922|20250922]] [[categories/cs.CV|cs.CV]]
**PDF**: [Download](https://arxiv.org/pdf/2509.15416.pdf)
**Category**: cs.CV
**Published**: 2025-09-22
**ArXiv ID**: [2509.15416](https://arxiv.org/abs/2509.15416)

## ğŸ”— ìœ ì‚¬í•œ ë…¼ë¬¸
- [[2025-09-19/Ensemble of Pathology Foundation Models for MIDOG 2025 Track 2_ Atypical Mitosis Classification_20250919|Ensemble of Pathology Foundation Models for MIDOG 2025 Track 2: Atypical Mitosis Classification]] (85.2% similar)
- [[2025-09-19/Mixture of Multicenter Experts in Multimodal AI for Debiased Radiotherapy Target Delineation_20250919|Mixture of Multicenter Experts in Multimodal AI for Debiased Radiotherapy Target Delineation]] (84.2% similar)
- [[2025-09-22/Temperature-Driven Robust Disease Detection in Brain and Gastrointestinal Disorders via Context-Aware Adaptive Knowledge Distillation_20250922|Temperature-Driven Robust Disease Detection in Brain and Gastrointestinal Disorders via Context-Aware Adaptive Knowledge Distillation]] (81.8% similar)
- [[2025-09-22/Uncertainty-Gated Deformable Network for Breast Tumor Segmentation in MR Images_20250922|Uncertainty-Gated Deformable Network for Breast Tumor Segmentation in MR Images]] (81.6% similar)
- [[2025-09-22/Self-supervised learning of imaging and clinical signatures using a multimodal joint-embedding predictive architecture_20250922|Self-supervised learning of imaging and clinical signatures using a multimodal joint-embedding predictive architecture]] (81.2% similar)

## ğŸ·ï¸ ì¹´í…Œê³ ë¦¬í™”ëœ í‚¤ì›Œë“œ
**ğŸ§  Broad Technical**: [[keywords/Foundation Model|Foundation Model]]
**ğŸ”— Specific Connectable**: [[keywords/Distributionally Robust Optimization|Distributionally Robust Optimization]], [[keywords/Self-supervised Learning|Self-supervised Learning]]
**âš¡ Unique Technical**: [[keywords/Neuro-oncology|Neuro-oncology]], [[keywords/Molecular Marker Prediction|Molecular Marker Prediction]]

## ğŸ“‹ ì €ì ì •ë³´

**Authors:** 

## ğŸ“„ Abstract (ì›ë¬¸)

arXiv:2509.15416v1 Announce Type: new 
Abstract: Neuro-oncology poses unique challenges for machine learning due to heterogeneous data and tumor complexity, limiting the ability of foundation models (FMs) to generalize across cohorts. Existing FMs also perform poorly in predicting uncommon molecular markers, which are essential for treatment response and risk stratification. To address these gaps, we developed a neuro-oncology specific FM with a distributionally robust loss function, enabling accurate estimation of tumor phenotypes while maintaining cross-institution generalization. We pretrained self-supervised backbones (BYOL, DINO, MAE, MoCo) on multi-institutional brain tumor MRI and applied distributionally robust optimization (DRO) to mitigate site and class imbalance. Downstream tasks included molecular classification of common markers (MGMT, IDH1, 1p/19q, EGFR), uncommon alterations (ATRX, TP53, CDKN2A/2B, TERT), continuous markers (Ki-67, TP53), and overall survival prediction in IDH1 wild-type glioblastoma at UCSF, UPenn, and CUIMC. Our method improved molecular prediction and reduced site-specific embedding differences. At CUIMC, mean balanced accuracy rose from 0.744 to 0.785 and AUC from 0.656 to 0.676, with the largest gains for underrepresented endpoints (CDKN2A/2B accuracy 0.86 to 0.92, AUC 0.73 to 0.92; ATRX AUC 0.69 to 0.82; Ki-67 accuracy 0.60 to 0.69). For survival, c-index improved at all sites: CUIMC 0.592 to 0.597, UPenn 0.647 to 0.672, UCSF 0.600 to 0.627. Grad-CAM highlighted tumor and peri-tumoral regions, confirming interpretability. Overall, coupling FMs with DRO yields more site-invariant representations, improves prediction of common and uncommon markers, and enhances survival discrimination, underscoring the need for prospective validation and integration of longitudinal and interventional signals to advance precision neuro-oncology.

## ğŸ” Abstract (í•œê¸€ ë²ˆì—­)

arXiv:2509.15416v1 ë°œí‘œ ìœ í˜•: ì‹ ê·œ  
ì´ˆë¡: ì‹ ê²½ì¢…ì–‘í•™ì€ ë°ì´í„°ì˜ ì´ì§ˆì„±ê³¼ ì¢…ì–‘ì˜ ë³µì¡ì„±ìœ¼ë¡œ ì¸í•´ ê¸°ê³„ í•™ìŠµì— ë…íŠ¹í•œ ë„ì „ ê³¼ì œë¥¼ ì œì‹œí•˜ë©°, ì´ëŠ” ê¸°ì´ˆ ëª¨ë¸(FMs)ì´ ì½”í˜¸íŠ¸ ì „ë°˜ì— ê±¸ì³ ì¼ë°˜í™”í•˜ëŠ” ëŠ¥ë ¥ì„ ì œí•œí•©ë‹ˆë‹¤. ê¸°ì¡´ì˜ FMsëŠ” ì¹˜ë£Œ ë°˜ì‘ê³¼ ìœ„í—˜ ê³„ì¸µí™”ì— í•„ìˆ˜ì ì¸ ë“œë¬¸ ë¶„ì ë§ˆì»¤ë¥¼ ì˜ˆì¸¡í•˜ëŠ” ë°ì—ë„ ì„±ëŠ¥ì´ ì €ì¡°í•©ë‹ˆë‹¤. ì´ëŸ¬í•œ ê²©ì°¨ë¥¼ í•´ê²°í•˜ê¸° ìœ„í•´, ìš°ë¦¬ëŠ” ì‹ ê²½ì¢…ì–‘í•™ì— íŠ¹í™”ëœ FMì„ ê°œë°œí–ˆìœ¼ë©°, ë¶„í¬ì ìœ¼ë¡œ ê°•ê±´í•œ ì†ì‹¤ í•¨ìˆ˜ë¥¼ ì‚¬ìš©í•˜ì—¬ ì¢…ì–‘ í‘œí˜„í˜•ì„ ì •í™•í•˜ê²Œ ì¶”ì •í•˜ë©´ì„œ ê¸°ê´€ ê°„ ì¼ë°˜í™”ë¥¼ ìœ ì§€í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë‹¤ê¸°ê´€ ë‡Œì¢…ì–‘ MRIì—ì„œ ìê°€ ì§€ë„ ë°±ë³¸(BYOL, DINO, MAE, MoCo)ì„ ì‚¬ì „ í•™ìŠµí•˜ê³ , ì‚¬ì´íŠ¸ ë° í´ë˜ìŠ¤ ë¶ˆê· í˜•ì„ ì™„í™”í•˜ê¸° ìœ„í•´ ë¶„í¬ì ìœ¼ë¡œ ê°•ê±´í•œ ìµœì í™”(DRO)ë¥¼ ì ìš©í–ˆìŠµë‹ˆë‹¤. í›„ì† ì‘ì—…ì—ëŠ” ì¼ë°˜ì ì¸ ë§ˆì»¤(MGMT, IDH1, 1p/19q, EGFR)ì˜ ë¶„ì ë¶„ë¥˜, ë“œë¬¸ ë³€í˜•(ATRX, TP53, CDKN2A/2B, TERT), ì—°ì† ë§ˆì»¤(Ki-67, TP53), UCSF, UPenn, CUIMCì—ì„œì˜ IDH1 ì•¼ìƒí˜• êµëª¨ì„¸í¬ì¢…ì˜ ì „ì²´ ìƒì¡´ ì˜ˆì¸¡ì´ í¬í•¨ë˜ì—ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ì˜ ë°©ë²•ì€ ë¶„ì ì˜ˆì¸¡ì„ ê°œì„ í•˜ê³  ì‚¬ì´íŠ¸ë³„ ì„ë² ë”© ì°¨ì´ë¥¼ ì¤„ì˜€ìŠµë‹ˆë‹¤. CUIMCì—ì„œ í‰ê·  ê· í˜• ì •í™•ë„ëŠ” 0.744ì—ì„œ 0.785ë¡œ, AUCëŠ” 0.656ì—ì„œ 0.676ìœ¼ë¡œ ì¦ê°€í–ˆìœ¼ë©°, ëŒ€í‘œì„±ì´ ë‚®ì€ ì—”ë“œí¬ì¸íŠ¸ì—ì„œ ê°€ì¥ í° í–¥ìƒì´ ìˆì—ˆìŠµë‹ˆë‹¤(CDKN2A/2B ì •í™•ë„ 0.86ì—ì„œ 0.92, AUC 0.73ì—ì„œ 0.92; ATRX AUC 0.69ì—ì„œ 0.82; Ki-67 ì •í™•ë„ 0.60ì—ì„œ 0.69). ìƒì¡´ ì˜ˆì¸¡ì˜ ê²½ìš°, ëª¨ë“  ì‚¬ì´íŠ¸ì—ì„œ c-indexê°€ ê°œì„ ë˜ì—ˆìŠµë‹ˆë‹¤: CUIMC 0.592ì—ì„œ 0.597, UPenn 0.647ì—ì„œ 0.672, UCSF 0.600ì—ì„œ 0.627. Grad-CAMì€ ì¢…ì–‘ ë° ì¢…ì–‘ ì£¼ë³€ ì˜ì—­ì„ ê°•ì¡°í•˜ì—¬ í•´ì„ ê°€ëŠ¥ì„±ì„ í™•ì¸í–ˆìŠµë‹ˆë‹¤. ì „ë°˜ì ìœ¼ë¡œ, FMsì™€ DROë¥¼ ê²°í•©í•˜ë©´ ì‚¬ì´íŠ¸ ë¶ˆë³€ í‘œí˜„ì´ ë” ì˜ ìƒì„±ë˜ê³ , ì¼ë°˜ì  ë° ë“œë¬¸ ë§ˆì»¤ì˜ ì˜ˆì¸¡ì´ ê°œì„ ë˜ë©°, ìƒì¡´ ì°¨ë³„í™”ê°€ í–¥ìƒë˜ì–´, ì •ë°€ ì‹ ê²½ì¢…ì–‘í•™ì„ ë°œì „ì‹œí‚¤ê¸° ìœ„í•œ ì „í–¥ì  ê²€ì¦ê³¼ ì¢…ì  ë° ê°œì… ì‹ í˜¸ì˜ í†µí•© í•„ìš”ì„±ì„ ê°•ì¡°í•©ë‹ˆë‹¤.

## ğŸ“ ìš”ì•½

ì´ ë…¼ë¬¸ì€ ì‹ ê²½ì¢…ì–‘í•™ì—ì„œ ê¸°ì´ˆ ëª¨ë¸(FM)ì˜ ì¼ë°˜í™” í•œê³„ë¥¼ ê·¹ë³µí•˜ê¸° ìœ„í•´ ì‹ ê²½ì¢…ì–‘ íŠ¹í™” FMì„ ê°œë°œí–ˆìŠµë‹ˆë‹¤. ì´ ëª¨ë¸ì€ ë¶„í¬ì ìœ¼ë¡œ ê°•ê±´í•œ ì†ì‹¤ í•¨ìˆ˜ë¥¼ ì‚¬ìš©í•˜ì—¬ ì¢…ì–‘ í‘œí˜„í˜•ì„ ì •í™•í•˜ê²Œ ì¶”ì •í•˜ê³  ê¸°ê´€ ê°„ ì¼ë°˜í™”ë¥¼ ìœ ì§€í•©ë‹ˆë‹¤. ë‹¤ì–‘í•œ MRI ë°ì´í„°ë¥¼ í™œìš©í•´ ì‚¬ì „ í•™ìŠµí•œ ìê°€ ì§€ë„ í•™ìŠµ ë°±ë³¸(BYOL, DINO, MAE, MoCo)ì„ ì‚¬ìš©í•˜ê³ , ë¶„í¬ì ìœ¼ë¡œ ê°•ê±´í•œ ìµœì í™”(DRO)ë¥¼ ì ìš©í•˜ì—¬ ë°ì´í„° ë¶ˆê· í˜•ì„ ì™„í™”í–ˆìŠµë‹ˆë‹¤. ì£¼ìš” ë°œê²¬ìœ¼ë¡œëŠ” ë“œë¬¸ ë¶„ì ë§ˆì»¤ ì˜ˆì¸¡ ì„±ëŠ¥ í–¥ìƒê³¼ ì‚¬ì´íŠ¸ ê°„ ì„ë² ë”© ì°¨ì´ ê°ì†Œê°€ ìˆìœ¼ë©°, CUIMCì—ì„œ í‰ê·  ê· í˜• ì •í™•ë„ì™€ AUCê°€ ê°ê° 0.744ì—ì„œ 0.785, 0.656ì—ì„œ 0.676ìœ¼ë¡œ í–¥ìƒë˜ì—ˆìŠµë‹ˆë‹¤. ìƒì¡´ ì˜ˆì¸¡ì—ì„œë„ ëª¨ë“  ì‚¬ì´íŠ¸ì—ì„œ c-indexê°€ ê°œì„ ë˜ì—ˆìŠµë‹ˆë‹¤. Grad-CAMì„ í†µí•´ ëª¨ë¸ì˜ í•´ì„ ê°€ëŠ¥ì„±ì„ í™•ì¸í–ˆìœ¼ë©°, ì´ ì—°êµ¬ëŠ” ì •ë°€ ì‹ ê²½ì¢…ì–‘í•™ ë°œì „ì„ ìœ„í•œ ì „í–¥ì  ê²€ì¦ í•„ìš”ì„±ì„ ê°•ì¡°í•©ë‹ˆë‹¤.

## ğŸ¯ ì£¼ìš” í¬ì¸íŠ¸

- 1. ì‹ ê²½ì¢…ì–‘í•™ ë¶„ì•¼ì˜ ê¸°ì´ˆ ëª¨ë¸ì€ ë°ì´í„°ì˜ ì´ì§ˆì„±ê³¼ ì¢…ì–‘ì˜ ë³µì¡ì„±ìœ¼ë¡œ ì¸í•´ ì¼ë°˜í™”ì— í•œê³„ê°€ ìˆë‹¤.
- 2. ê¸°ì¡´ì˜ ê¸°ì´ˆ ëª¨ë¸ì€ ì¹˜ë£Œ ë°˜ì‘ê³¼ ìœ„í—˜ ê³„ì¸µí™”ì— í•„ìˆ˜ì ì¸ ë“œë¬¸ ë¶„ì ë§ˆì»¤ ì˜ˆì¸¡ì— ì·¨ì•½í•˜ë‹¤.
- 3. ë³¸ ì—°êµ¬ì—ì„œëŠ” ë¶„í¬ì ìœ¼ë¡œ ê°•ê±´í•œ ì†ì‹¤ í•¨ìˆ˜ë¥¼ ì‚¬ìš©í•˜ì—¬ ì¢…ì–‘ í‘œí˜„í˜•ì„ ì •í™•íˆ ì¶”ì •í•˜ê³  ê¸°ê´€ ê°„ ì¼ë°˜í™”ë¥¼ ìœ ì§€í•˜ëŠ” ì‹ ê²½ì¢…ì–‘í•™ íŠ¹í™” ê¸°ì´ˆ ëª¨ë¸ì„ ê°œë°œí•˜ì˜€ë‹¤.
- 4. ë‹¤ê¸°ê´€ ë‡Œì¢…ì–‘ MRIë¥¼ í™œìš©í•œ ìê°€ ì§€ë„ í•™ìŠµ ë°±ë³¸ì„ ì‚¬ì „ í›ˆë ¨í•˜ê³ , ë¶„í¬ì ìœ¼ë¡œ ê°•ê±´í•œ ìµœì í™”ë¥¼ ì ìš©í•˜ì—¬ ì‚¬ì´íŠ¸ ë° í´ë˜ìŠ¤ ë¶ˆê· í˜•ì„ ì™„í™”í•˜ì˜€ë‹¤.
- 5. ì œì•ˆëœ ë°©ë²•ì€ ë¶„ì ì˜ˆì¸¡ì„ ê°œì„ í•˜ê³  ì‚¬ì´íŠ¸ ê°„ ì„ë² ë”© ì°¨ì´ë¥¼ ì¤„ì´ë©°, ìƒì¡´ ì˜ˆì¸¡ì˜ c-ì§€ìˆ˜ë¥¼ í–¥ìƒì‹œì¼°ë‹¤.


---

*Generated on 2025-09-23 11:57:30*